Results 1 to 10 of about 517 (142)

Brusatol Suppresses STAT3-Driven Metastasis by Downregulating Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma [PDF]

open access: yesJournal of Advanced Research, 2020
Introduction: Epithelial-mesenchymal transition (EMT) is a process of transdifferentiation where epithelial cells attain mesenchymal phenotype to gain invasive properties and thus, can contribute to metastasis of tumor cells.
Arunachalam Chinnathambi   +2 more
exaly   +4 more sources

Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation

open access: yesBiomedicines, 2022
Acute lymphoblastic leukemia (ALL) is one of the most common hematological malignancies at pediatric ages and is characterized by different chromosomal rearrangements and genetic abnormalities involved in the differentiation and proliferation of lymphoid
Joana Jorge   +5 more
doaj   +2 more sources

The toxic effects and possible mechanisms of Brusatol on mouse oocytes. [PDF]

open access: yesPLoS ONE, 2017
Brusatol is a natural quassinoid that shows a potential therapeutic use in cancer models by the inhibition of Nuclear factor erythroid 2-related factor 2 (Nrf2) and is capable of inducing a variety of biological effects. The effects of Brusatol on oocyte
Rujun Ma   +6 more
doaj   +4 more sources

Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1 [PDF]

open access: yesFrontiers in Pharmacology, 2021
Brusatol (Bru), a Chinese herbal extract, has a variety of anti-tumor effects. However, little is known regarding its role and underlying mechanism in glioblastoma cells.
Zhang’an Dai   +10 more
doaj   +3 more sources

Targeting NRF2 Sensitizes Esophageal Adenocarcinoma Cells to Cisplatin through Induction of Ferroptosis and Apoptosis

open access: yesAntioxidants, 2022
Esophageal adenocarcinoma (EAC), the predominant type of esophageal cancer in the United States, develops through Barrett’s esophagus (BE)-dysplasia-carcinoma cascade. Gastroesophageal reflux disease, where acidic bile salts refluxate into the esophagus,
Farah Ballout   +7 more
doaj   +2 more sources

The Nrf2 Inhibitor Brusatol Synergistically Enhances the Cytotoxic Effect of Lapatinib in HER2-Positive Cancers

open access: yesHeliyon, 2022
The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. However, a majority of patients do not respond to lapatinib therapy within 6 months. Therefore, potentiating the anti-tumor effect
Ge Chunpo
exaly   +3 more sources

Characterization of Brusatol Self-Microemulsifying Drug Delivery System and Its Therapeutic Effect Against Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice

open access: yesDrug Delivery, 2017
Brusatol (BR) is one of the main bioactive components derived from Brucea javanica, a medicinal herb historically used in the treatment of dysenteric disorders (also known as ulcerative colitis(UC)).
Jianhui Xie, Ping Huang, Lihua Tan
exaly   +2 more sources

Targeting tumor glycolysis metabolism in oral squamous cell carcinoma cells by brusatol

open access: yesPharmacological Research - Modern Chinese Medicine, 2022
Brusatol is a natural quassinoid terpenoid that shows a potential therapeutic use in treating various ailments. Recently, brusatol was shown to have anti-tumor activity and ameliorating chemoresistance or enhancing chemotherapeutic drug efficacy in vitro
Guilian Zhang   +6 more
doaj   +1 more source

Brusatol inhibits proliferation, migration, and invasion of nonsmall cell lung cancer PC-9 cells

open access: yesWorld Journal of Traditional Chinese Medicine, 2023
Objective: The purpose of this study was to investigate the inhibitory effect of brusatol, a nigakilactone extracted from Brucea javanica, on lung cancer for development of therapeutic drugs.
Lu-Ming Yang   +9 more
doaj   +1 more source

Brusatol From Suppresses Arsenic Trioxide-Induced PD-L1 Upregulation Through Inhibition of NRF2 in Leukemia Cells

open access: yesNatural Product Communications, 2022
Overexpression of programed death-ligand 1 (PD-L1) is associated with poor prognosis in leukemia. Moreover, antitumor pharmaceuticals have been shown to induce immunoresistance, leading to reduced efficacy.
Shunji Zhang   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy